Promoters Venkateswarlu Jasti and his family split Suven Life Sciences in FY20, turning the CRAMS business into a separately listed company via a demerger. The promoters own 60% of the company, which has a market value of ₹12,278.94 crore, based on the Thursday close.

Advent closes in on Suven Pharma buyout

We zoom in on the prospects of Tech Mahindra, as also that of two other stocks — TTK Prestige and Suven Life Sciences

Tech Query: Is the trend in Tech Mahindra reversing?

Suven Life Sciences’ record date for rights issue has been fixed on 18th October 2022

Suven Life Science rights issue: Record date announced. 5 things you should know

Suven Life Sciences rose 2.19% to Rs 72.30 after the company said its board approved the terms of its upcoming rights issue.

Suven Life gains after unveiling terms of rights issue

The company said the board of directors has approved rights issue size of 7,26,91,239 shares for Rs399.80 crore.

Suven Life Sciences gains 4% on receiving approval to raise Rs400 crore via rights issue

Suven Life Sciences Ltd is a small-cap company with a market capitalization of ₹1,028.58 crore that operates in the pharmaceutical industry

Multibagger stock surges 606% in 5 years, fixes record date for 1:2 rights issue

Suven Life Sciences reports consolidated net loss of Rs 16.33 crore in the June 2022 quarter

The board of Suven Life Sciences approved raising upto Rs 400 crore by issuing equity shares on right basis.

Suven Life board approves rights issue

Suven Life Sciences has also increased its authorised share capital to Rs 30 crore from Rs 20 crore, subject to approval of shareholders.

Suven Life Sciences Plans To Raise Up To Rs 400 Crore Through Rights Issue

The board of Suven Life Sciences approved funding up to Rs400 crore through the issuance of equity shares on a rights basis, the company announced on Friday.

Suven Life Sciences to raise up to Rs 400 crore through rights issue; stock slips 0.72%

Bharat Forge: The company has approved the transfer of its stake in Refu Drive GmbH (Refu), joint venture (JV) company to Kalyani Powertrain in order to house all the electric vehicle investments of the company under one entity.

Bharat Forge, Fineotex Chemical, Suven Life Sciences in focus

Hasn't faired well - amongst the low performers

Performance

Seems to be overvalued vs the market average

Valuation

Lagging behind the market in financials growth

Growth

Profitability and efficiency haven't been upto the mark

Profitability

Fundamentals

Good time to consider, stock is not in the overbought zone

Technicals

Entry point

Promoter pledged holding

Unsolicited messages

Default probability

Red flags

Suven Life Sciences Limited is a bio-pharmaceutical company, engaged in the business of manufacture and sale of bulk drugs and intermediaries.